Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
10 déc. 2024 07h00 HE
|
Apogee Therapeutics
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus...
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
02 déc. 2024 06h00 HE
|
Apogee Therapeutics
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition...
Apogee Therapeutics Announces Agenda for Virtual R&D Day
29 nov. 2024 13h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
18 nov. 2024 07h30 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
12 nov. 2024 07h00 HE
|
Apogee Therapeutics
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2...
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
04 nov. 2024 07h30 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
24 oct. 2024 08h00 HE
|
Apogee Therapeutics
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved...
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
16 oct. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
12 sept. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
09 sept. 2024 07h00 HE
|
Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...